» Articles » PMID: 37903524

Risk of Hospital Admission and Death from First-ever SARS-CoV-2 Infection by Age Group During the Delta and Omicron Periods in British Columbia, Canada

Overview
Journal CMAJ
Date 2023 Oct 30
PMID 37903524
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Population-based cross-sectional serosurveys within the Lower Mainland, British Columbia, Canada, showed about 10%, 40% and 60% of residents were infected with SARS-CoV-2 by the sixth (September 2021), seventh (March 2022) and eighth (July 2022) serosurveys. We conducted the ninth (December 2022) and tenth (July 2023) serosurveys and sought to assess risk of severe outcomes from a first-ever SARS-CoV-2 infection during intersurvey periods.

Methods: Using increments in cumulative infection-induced seroprevalence, population census, discharge abstract and vital statistics data sets, we estimated infection hospitalization and fatality ratios (IHRs and IFRs) by age and sex for the sixth to seventh (Delta/Omicron-BA.1), seventh to eighth (Omicron-BA.2/BA.5) and eighth to ninth (Omicron-BA.5/BQ.1) intersurvey periods. As derived, IHR and IFR estimates represent the risk of severe outcome from a first-ever SARS-CoV-2 infection acquired during the specified intersurvey period.

Results: The cumulative infection-induced seroprevalence was 74% by December 2022 and 79% by July 2023, exceeding 80% among adults younger than 50 years but remaining less than 60% among those aged 80 years and older. Period-specific IHR and IFR estimates were consistently less than 0.3% and 0.1% overall. By age group, IHR and IFR estimates were less than 1.0% and up to 0.1%, respectively, except among adults aged 70-79 years during the sixth to seventh intersurvey period (IHR 3.3% and IFR 1.0%) and among those aged 80 years and older during all periods (IHR 4.7%, 2.2% and 3.5%; IFR 3.3%, 0.6% and 1.3% during the sixth to seventh, seventh to eighth and eighth to ninth periods, respectively). The risk of severe outcome followed a J-shaped age pattern. During the eighth to ninth period, we estimated about 1 hospital admission for COVID-19 per 300 newly infected children younger than 5 years versus about 1 per 30 newly infected adults aged 80 years and older, with no deaths from COVID-19 among children but about 1 death per 80 newly infected adults aged 80 years and older during that period.

Interpretation: By July 2023, we estimated about 80% of residents in the Lower Mainland, BC, had been infected with SARS-CoV-2 overall, with low risk of hospital admission or death; about 40% of the oldest adults, however, remained uninfected and at highest risk of a severe outcome. First infections among older adults may still contribute substantial burden from COVID-19, reinforcing the need to continue to prioritize this age group for vaccination and to consider them in health care system planning.

Citing Articles

Ratio of Infections to COVID-19 Cases and Hospitalizations in the United States based on SARS-CoV-2 Seroprevalence Data, September 2021-February 2022.

Deng Y, Kim Y, Bratcher A, Jones J, Simuzingili M, Gundlapalli A Open Forum Infect Dis. 2025; 12(1):ofae719.

PMID: 39822271 PMC: 11736415. DOI: 10.1093/ofid/ofae719.


Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan.

Kakugawa T, Mimura Y, Mimura-Kimura Y, Doi K, Ohteru Y, Kakugawa H Immun Ageing. 2024; 21(1):41.

PMID: 38909235 PMC: 11193299. DOI: 10.1186/s12979-024-00444-1.


2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).

Skowronski D, Zhan Y, Kaweski S, Sabaiduc S, Khalid A, Olsha R Euro Surveill. 2024; 29(7).

PMID: 38362622 PMC: 10986657. DOI: 10.2807/1560-7917.ES.2024.29.7.2400076.

References
1.
Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View

2.
ODriscoll M, Ribeiro Dos Santos G, Wang L, Cummings D, Azman A, Paireau J . Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020; 590(7844):140-145. DOI: 10.1038/s41586-020-2918-0. View

3.
Harrigan S, Wilton J, Chong M, Abdia Y, Velasquez Garcia H, Rose C . Clinical Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Relative to Delta in British Columbia, Canada: A Retrospective Analysis of Whole-Genome Sequenced Cases. Clin Infect Dis. 2022; 76(3):e18-e25. PMC: 9452171. DOI: 10.1093/cid/ciac705. View

4.
Charlton C, Kanji J, Tran V, Kus J, Gubbay J, Osiowy C . Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. Can Commun Dis Rep. 2021; 47(4):171-183. PMC: 8127682. DOI: 10.14745/ccdr.v47i04a01. View

5.
Link-Gelles R, Ciesla A, Fleming-Dutra K, Smith Z, Britton A, Wiegand R . Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(48):1526-1530. PMC: 9721148. DOI: 10.15585/mmwr.mm7148e1. View